No Data
Safe, BASE etc. (additional) Rating
Upgraded - bullish Code Stock Name Securities Company Previous After Change ----------------------------------------------------- <4912> Lion Daiwa "3" "2" <9682> DTS Daiwa "3" "2" Downgraded - bearish Code Stock Name Securities Company Previous After Change ----------------------------------------------------- <3436> SUMCO Nomura "
Nissho, Nichias etc (additional) Rating
Upgraded - bullish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------------- <4967> Kobayashi Pharmaceutical Mizuho "hold" "buy" <6481> THK City "2" "1" <7186> Concordia JPM "Neutral" "OverW" <7202> Isuzu Mizuho "hold" "buy" Downgraded - bearish Code Stock Name Brokerage Firm Previous Change After -----
Stocks that moved the day before part 1: Qualips, ID & EHD, KADOKAWA, etc.
Stock name <Code> 20-day closing price ⇒ Previous day comparison Geocode <7357> 652 +41.25 The fiscal year ending February 5th is expected to increase the dividends by 5 yen compared to the previous period including the 20th anniversary of establishment. Morito <9837> 1511 +67.24 Revised upward the dividend estimate for the fiscal year ending November 2024, also announced the presentation of 35th anniversary commemorative goods. Rohto Yakuhin <4527> 2718 -68.5 Foreign securities firms downgraded their investment rating by 2 levels. Qualipsis <4894> 4975 +70.0 Submitted some of the clinical related application documents to the PMDA, for approval application.
Jefferies Downgrades Rohto Pharmaceutical to Underperform From Buy, Adjusts Price Target to 2,450 Yen From 3,900 Yen
Rohto Pharmaceutical---decline, the potential for a two-step downgrade in valuation by US securities firms
Rohto Pharmaceutical Co., Ltd. (4527) fell. Jefferies Securities has downgraded its investment rating from "Buy" to "underperform" in a two-step downgrade. The target stock price is set at 2450 yen. The performance for the July-September quarter reflects the slowdown in the growth of skincare in Japan, increased cost rates, advertising and publicity expenses, and research and development costs, with a potential decrease in profit margins and valuations in the near term. For the fiscal year ending March 2025, the operating profit is expected to be 40.5 billion yen, lower than the consensus of 44.3 billion yen.
Rating [security companies rating]
Upgraded - bullish code stock name brokerage firm previous change after ----------------------------------------------------------------- <7839> SHOEISMBC Nikko "2" "1" <4208> UBE Daiwa "3" "2" <4004> Resonac HD Iwai Cosmo "B+" "A" <4886> Asuka Pharmaceutical HD Toyo "Hold" "Buy" <4967> Kobayashi Pharmaceutical Jefferies "Under P" "
No Data
